evipedia.ai
← Back

Niacinamide for Health & Longevity

Evidence Review created on 08/26/2026 using AI4L / Opus 5

Also known as: Nicotinamide, Vitamin B3 (Amide Form), Nicotinic Acid Amide, 3-Pyridinecarboxamide

Motivation

Niacinamide (also called nicotinamide) is one of the two common forms of vitamin B3. Unlike the other form, nicotinic acid, it does not cause the hot, red skin flush many people associate with the vitamin, and it does not change cholesterol. Interest in it rests on one job: cells use it to rebuild a helper molecule that powers energy production and the repair of damaged genetic material, and that supply falls with age.

Vitamin B3 entered medicine in the 1930s, when it cured a deficiency disease that once killed thousands of people a year. Since then niacinamide has been given at doses hundreds of times larger than the amount needed to prevent deficiency — first to try to delay type 1 diabetes, later to prevent sun-driven skin cancers, and most recently to protect the optic nerve. It is inexpensive, sold without a prescription, and widely added to skin creams.

This review examines the human evidence for niacinamide taken by mouth and applied to the skin: where findings are strongest, where large trials returned nothing, which doses were tested, what harms appear at gram-level intakes, and how its effects are measured.

Benefits - Risks - Protocol - Conclusion

High-level overviews of niacinamide and of the cellular pathway it feeds, from longevity-focused clinicians and researchers, a consumer-health publisher, and a longevity research organisation.

Note on priority sources: Chris Kresser was searched directly and is not listed above. Chriskresser.com’s own site search returns no results for niacinamide, and its skin-nutrition writing treats vitamin B3 only as a dietary nutrient.

Grokipedia

Nicotinamide

Covers the compound’s chemistry, its role in NAD⁺ metabolism, dietary sources and intake reference values, and its medical applications, with a dedicated pharmacology-and-safety section on high-dose use.

Examine

Nicotinamide

Grades the outcome evidence directly — an A for acne symptoms, lower grades elsewhere — and separates oral dose ranges (25 mg to 6 g daily) from topical concentrations (1–5%).

ConsumerLab

B Vitamin Supplements Review (B Complexes, B6, B12, Biotin, Folate, Niacin, Riboflavin & More)

Reports independent assay results for niacin and niacinamide products, names its Top Picks, and flags label inaccuracy as the dominant quality problem in this category. Access requires a paid subscription.

Systematic Reviews

Systematic reviews and meta-analyses covering niacinamide’s two best-studied claims — skin cancer prevention and dermatological use — alongside the reviews that quantify its principal harm, gastrointestinal intolerance.

Mechanism of Action

Niacinamide is the direct substrate of the NAD⁺ salvage pathway. Nicotinamide phosphoribosyltransferase (NAMPT, the rate-limiting enzyme that recycles used nicotinamide back into the pathway) converts it to NMN, which is then converted to NAD⁺. NAD⁺ carries electrons for adenosine triphosphate (ATP, the cell’s energy currency) production and is consumed as a substrate by two enzyme families: poly-ADP-ribose polymerases (PARPs, which repair DNA breaks) and sirtuins (NAD⁺-dependent enzymes that switch metabolic and repair programmes on and off). Ultraviolet light drains cellular ATP and NAD⁺; restoring the pool is the proposed basis for faster DNA repair and reduced ultraviolet-induced immune suppression in skin.

A competing mechanistic reading exists. Niacinamide is also the reaction product of sirtuins and PARPs, and in cell-free assays it inhibits them by product feedback — the argument that gram-level dosing could blunt the very longevity signalling it is taken to support. Cell-based work finds the opposite: at achievable intracellular concentrations niacinamide raises NAD⁺ and behaves as a sirtuin stimulator rather than an inhibitor (Hwang & Song, 2017).

Pharmacologically, niacinamide is a small, water-soluble vitamin with no receptor selectivity — it does not activate the niacin receptor HCA2 that causes flushing. It distributes widely, including into skin and the eye. Clearance is hepatic methylation by nicotinamide N-methyltransferase (NNMT, which tags it with a methyl group for disposal) followed by oxidation to the terminal metabolites 2PY and 4PY and renal excretion. It is not a cytochrome P450 (CYP) substrate. Plasma half-life is a few hours, so gram-level protocols are split.

Historical Context & Evolution

Nicotinamide was isolated in 1937 as the liver factor that cured pellagra (severe vitamin B3 deficiency causing rash, diarrhoea and confusion), then endemic in maize-dependent populations. Its original use was purely nutritional: correcting a deficiency at milligram doses.

Interest in supra-nutritional dosing followed animal work in the 1980s showing that nicotinamide inhibits PARP and preserves pancreatic beta-cell NAD⁺, which protected rodents from autoimmune diabetes. That produced the largest trial the compound has ever had, ENDIT, which randomised 552 antibody-positive relatives to five years of modified-release nicotinamide or placebo. It found no delay in diabetes onset (adjusted hazard ratio 1.01, meaning no difference in risk between groups; 95% confidence interval — the range the true value most likely falls in — 0.73–1.38). The finding is a clean negative on that indication, not a refutation of the compound: the same trial and its accompanying safety review established that multi-gram daily dosing is tolerable for years, which is why later fields could use it.

In parallel, radiation oncology used nicotinamide as a tumour radiosensitiser, and dermatology used it with tetracycline as a steroid-sparing option in the blistering disease bullous pemphigoid (Fivenson et al., 1994). The Sydney group then reframed it as a DNA-repair agent for sun-damaged skin, leading to the chemoprevention trials of the 2010s. The NAD⁺-and-ageing literature of the last decade added a fourth framing — niacinamide as the cheapest NAD⁺ precursor — while commercial attention shifted to the patentable derivatives NR and NMN.

Expected Benefits

High 🟩 🟩 🟩

Prevention of New Keratinocyte Carcinomas After Prior Skin Cancer ⚠️ Conflicted

Gram-level oral niacinamide accelerates repair of ultraviolet-damaged DNA and limits ultraviolet-induced immune suppression, both plausible routes to fewer new keratinocyte carcinomas (the basal and squamous cell skin cancers). The ONTRAC phase 3 trial and a meta-analysis of five RCTs both found reductions, and a 33,822-person cohort reproduced them. But a transplant-recipient trial and a second meta-analysis found nothing. Net reading: the effect is real in sun-damaged people with intact immunity and starting soon after a first cancer, and absent under immunosuppression.

Magnitude: 23% lower rate of new keratinocyte carcinomas at 12 months (95% confidence interval 4–38%) and 13% fewer actinic keratoses (rough precancerous sun-damage patches) in ONTRAC; 14% overall risk reduction rising to 54% when started after a first skin cancer in the cohort study.

Improved Appearance of Photoaged Facial Skin

Topical niacinamide raises ceramide and free fatty acid synthesis in the stratum corneum (the skin’s outer barrier layer) and blocks pigment transfer from pigment-producing cells to keratinocytes. Repeated randomised, vehicle-controlled split-face trials at 5% show improvement in wrinkles, sallowness, blotchiness, hyperpigmented spots and elasticity (Bissett et al., 2005; Bissett et al., 2004), with a larger vehicle-controlled trial confirming the pigment effect (Kimball et al., 2010). Effects are cosmetic-grade rather than structural, and reverse on stopping.

Magnitude: Statistically significant reductions in fine lines and wrinkles, hyperpigmented spots, red blotchiness and yellowing, plus improved instrument-measured elasticity, over 12 weeks of twice-daily 5% application versus vehicle on the contralateral face.

Reduction of Inflammatory Acne Lesions

Topical niacinamide suppresses inflammatory signalling in sebaceous and immune cells without antimicrobial action, so it does not select for resistant organisms. A double-blind trial found 4% gel equivalent to 1% clindamycin over eight weeks (Shalita et al., 1995). The Cochrane review confirms comparable withdrawal and adverse-event rates across four such comparisons but rates the efficacy evidence low-quality because global assessment was not measured.

Magnitude: 60% reduction in papules and pustules and 52% reduction in acne severity at eight weeks with 4% nicotinamide gel, versus 43% and 38% with 1% clindamycin gel; the between-group differences were not significant.

Medium 🟩 🟩

Protection Against Ultraviolet-Induced Immune Suppression in Skin

Even sub-sunburn ultraviolet doses suppress cutaneous immune surveillance, a step in skin carcinogenesis. In randomised crossover studies using the Mantoux delayed-type hypersensitivity model (a standardised skin immune-response test), oral niacinamide preserved the response at both 500 mg and 1,500 mg daily, with no effect on unirradiated skin (Yiasemides et al., 2009). The same protection appeared against photodynamic-therapy-induced suppression (Thanos et al., 2012). The endpoint is a functional immune measure, not a disease outcome.

Magnitude: Immunosuppression reduced by 66% with 500 mg twice daily against high-irradiance photodynamic therapy, and by 59% with 5% topical lotion; ultraviolet-driven suppression was significantly reduced at both 500 mg and 1,500 mg daily.

Lower Serum Phosphate in Dialysis-Dependent Kidney Disease ⚠️ Conflicted

Niacinamide inhibits the intestinal sodium-phosphate cotransporter, a mechanism distinct from binding phosphate in the gut. A crossover RCT in haemodialysis patients lowered serum phosphorus and raised HDL cholesterol (high-density lipoprotein, the “good” cholesterol) (Cheng et al., 2008). The larger COMBINE trial in non-dialysis stage 3b/4 disease found no phosphate or FGF23 (fibroblast growth factor 23, a phosphate-regulating hormone) effect, with gastrointestinal symptoms limiting adherence. Net reading: the effect holds where phosphate load is high and adherence enforced, and disappears earlier in the disease.

Magnitude: Serum phosphorus fell from 6.26 to 5.47 mg/dL on 500–1,500 mg daily (6.45 to 5.28 mg/dL among adherent patients), with HDL cholesterol rising from 50 to 61 mg/dL; no change in either endpoint in stage 3b/4 disease.

Low 🟩

Reversal of Vitamin B3 Deficiency

Niacinamide corrects pellagra reliably at about 300 mg daily — the only indication where it acts as an essential nutrient rather than a drug. The effect is clinically undoubted, but the human evidence is uncontrolled historical case series, which caps the grade (Knip et al., 2000).

Magnitude: Not quantified in available studies. Pellagra was effectively eliminated by food fortification before controlled trials of treatment were conducted, so no randomised comparison of dose against symptom resolution exists.

Improved Inner Retinal Function in Treated Glaucoma ⚠️ Conflicted

Serum niacinamide is low in glaucoma, and repletion protects retinal ganglion cells in animals. Crossover RCTs improved the photopic negative response, an electrical retinal signal (Hui et al., 2020; Ha et al., 2026). Net reading: the electrical signal moves, the validated visual-field endpoint does not.

Magnitude: Saturated photopic negative response amplitude improved 14.8% and its ratio 12.6% on 1.5–3.0 g daily; visual field mean deviation improved by 0.10 dB, which is not significant.

Higher HDL Cholesterol at Gram-Level Doses

Unlike nicotinic acid, niacinamide is not considered lipid-active because it does not engage the flushing receptor. One crossover RCT nonetheless recorded a substantial HDL rise in dialysis patients, unreplicated elsewhere and confined to a population with disturbed lipid handling (Cheng et al., 2008).

Magnitude: HDL cholesterol rose from 50 to 61 mg/dL over eight weeks on 500–1,500 mg daily, with LDL (low-density lipoprotein) cholesterol, total cholesterol and triglycerides unchanged.

Speculative 🟨

Healthspan Support Through Restored NAD⁺ Availability

Chronic niacinamide improved glucose handling and liver fat in high-fat-fed mice without extending lifespan (Mitchell et al., 2018). No human trial has measured an ageing or survival outcome; the basis is animal work only.

Reduced Cellular Senescence and Mitochondrial Decline

Cell and animal models show niacinamide restoring mitochondrial function and limiting senescent-cell accumulation via NAD⁺ repletion. No controlled human study has measured senescence burden or mitochondrial capacity after niacinamide; the basis is mechanistic only.

Benefit-Modifying Factors

  • NNMT and NAMPT expression: Individual differences in nicotinamide N-methyltransferase and NAMPT set how much of a dose is disposed of versus recycled into NAD⁺. High disposal capacity shifts a given dose toward the terminal metabolites rather than toward the coenzyme pool.

  • Baseline niacinamide status: Serum niacinamide is measurably low in glaucoma, and the Hui crossover trial recruited on that premise. People already replete from diet or fortified food have the least headroom for a supra-nutritional dose to change anything.

  • Prior skin cancer count and timing: Benefit was largest when treatment began after a first keratinocyte carcinoma and declined with each subsequent one (Breglio et al., 2025). Field cancerisation (widespread precancerous change across a sun-exposed area) that is already extensive appears less modifiable.

  • Sex: No sex-stratified efficacy difference has been reported. Inference for women is nonetheless weak on the chemoprevention side: the largest cohort was 98% male, and women were 2% of participants.

  • Immunosuppression and transplant status: Pharmacological immunosuppression abolished the chemoprevention effect in ONTRANS, consistent with a mechanism that depends on intact cutaneous immune surveillance rather than on DNA repair alone.

  • Age: NAD⁺ availability declines with age, so older adults are the group with the most theoretical headroom — and the ONTRAC and cohort populations averaged 66 and 77 years. Older skin also carries the accumulated ultraviolet damage the effect acts on.

  • Chronic kidney disease: Reduced renal clearance raises exposure to niacinamide and its metabolites at any given dose, and the phosphate-lowering effect itself is confined to advanced disease.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Upset and Reduced Adherence

Nausea, dyspepsia (indigestion), bloating and diarrhoea are the dose-limiting effects of gram-level niacinamide, most likely from direct mucosal and osmotic effects in the gut rather than a systemic mechanism. The Mainville meta-analysis found a significant excess of digestive adverse events versus control. In COMBINE gastrointestinal symptoms limited adherence enough to compromise the trial. Symptoms are reversible on dose reduction and largely absent at the 500 mg twice-daily dermatology dose.

Magnitude: Direction is consistent across trials and rises steeply above roughly 1.5 g daily and with immediate-release formulations. A network meta-analysis of eleven phosphate-lowering agents ranked nicotinamide highest for gastrointestinal events; these reviews report no pooled incidence figure.

Medium 🟥 🟥

Reversible Liver Enzyme Elevation at Gram-Level Doses

Hepatic loading with a substrate cleared by methylation can produce transaminase rises and, at extreme doses, frank hepatotoxicity, documented in both animals and humans in the dedicated safety review. Abnormalities were infrequent and reversible at the doses used for diabetes prevention, and were not seen in excess in ONTRAC or ONTRANS. Risk concentrates in sustained-release preparations and pre-existing liver disease.

Magnitude: Minor liver enzyme abnormalities occur infrequently at 1.2 g/m² daily; the review sets the threshold for treating niacinamide as a drug with toxic potential at adult doses above 3 g/day, and reports reversible hepatotoxicity above that.

Methyl-Group Consumption and Raised Homocysteine

Every molecule of niacinamide cleared is methylated by NNMT, drawing on S-adenosylmethionine (the body’s universal methyl donor) and therefore on betaine and choline. A randomised human comparison of 300 mg nicotinic acid against 300 mg nicotinamide found nicotinamide consumed markedly more betaine and raised homocysteine (an amino acid whose elevation tracks impaired methylation) more (Sun et al., 2017). Evidence is a single acute-dosing study; chronic effects are unmeasured.

Magnitude: Three hours after a single 300 mg dose, plasma homocysteine was 61% higher and plasma betaine 24.4% lower than control, with urinary excretion of the terminal metabolite 2PY 1,728% higher.

Low 🟥

Cardiovascular Risk Signal From Terminal Metabolites ⚠️ Conflicted

Excess vitamin B3 in any form ends as 2PY and 4PY. Across three cardiac cohorts both metabolites predicted major adverse cardiovascular events, and 4PY drove vascular inflammation in mice (Ferrell et al., 2024). Net reading: the association is observational, and niacinamide trials recorded no excess cardiac events.

Magnitude: Adjusted hazard ratios for three-year major adverse cardiovascular events of 1.64 and 2.02 for 2PY and 1.89 and 1.99 for 4PY across two validation cohorts.

Reduced Insulin Sensitivity ⚠️ Conflicted

High-dose niacinamide has been reported to produce minor insulin resistance, plausibly through NAD⁺-driven substrate competition, but studies of glucose kinetics are inconsistent (Knip et al., 2000). Five years of dosing in ENDIT did not impair first-phase insulin secretion. Net reading: any effect is small and not reliably reproducible.

Magnitude: Direction is toward mild insulin resistance and appears only at multi-gram doses; the safety review describes the underlying glucose-kinetic studies as inconsistent and reports no pooled effect figure.

Local Skin Irritation From Topical Use

Stinging, burning, dryness, desquamation (skin peeling) and itch are the recognised local effects of topical pigment and barrier agents, niacinamide included (Tan et al., 2022). Attribution is imprecise because most products combine niacinamide with acids or retinoids.

Magnitude: Direction is consistent and severity rises with concentration and with co-formulated low-pH acids; the systematic review reports these effects qualitatively and gives no pooled incidence figure.

Speculative 🟨

Tumour Promotion in Susceptible Tissue

At very high doses niacinamide potentiated islet tumour formation in rats pre-treated with beta-cell toxins, and PARP inhibition is theoretically pro-mutagenic. No human signal exists; the basis is animal work and mechanism only.

Suppression of Sirtuin-Dependent Longevity Signalling

Because niacinamide is the product of sirtuin reactions, cell-free assays show it inhibiting them, raising the concern that gram-level dosing opposes the pathway it supports. Cell-based work contradicts this. No human outcome data exist.

Risk-Modifying Factors

  • NNMT and AOX1 variants: Variation in nicotinamide N-methyltransferase and in aldehyde oxidase 1 (the enzyme oxidising the methylated product) shifts how fast 2PY and 4PY accumulate, and therefore individual exposure to the metabolites carrying the cardiovascular signal.

  • MTHFR and COMT variants: MTHFR (an enzyme regenerating the body’s methyl supply) and COMT (a methyl-consuming enzyme clearing stress hormones) compete with niacinamide disposal for the same methyl pool, so reduced-function variants amplify the homocysteine rise.

  • Baseline liver enzymes and homocysteine: Elevated transaminases or homocysteine before starting identify the two organ systems where gram-level dosing has documented biochemical effects, and mark the people with least reserve.

  • Reduced kidney function: Niacinamide and both terminal metabolites are renally cleared, so a low eGFR (estimated glomerular filtration rate, a measure of kidney filtering capacity) raises exposure at any given dose.

  • Sex: Doses are prescribed as fixed milligram amounts rather than per kilogram, so women receive a higher exposure per unit body weight. No sex-specific adverse-event difference has been reported in the trials.

  • Pre-existing liver disease, diabetes and peptic ulcer: Impaired hepatic clearance, an existing glycaemic margin and existing mucosal injury each intersect directly with the three documented harm pathways.

  • Age: Renal clearance falls with age and polypharmacy rises, so older adults accumulate metabolites faster; against this, the trial populations demonstrating tolerability were themselves elderly.

Key Interactions & Contraindications

  • Anticonvulsants (carbamazepine, primidone): Caution. Case reports describe niacinamide raising plasma levels of both, risking sedation and ataxia (unsteady, uncoordinated movement). Measure drug levels before and four weeks after starting gram-level niacinamide.

  • Isoniazid and other niacin antagonists: Monitor. Isoniazid blocks conversion of tryptophan to niacin and can precipitate deficiency; niacinamide corrects this rather than conflicting with it, so co-administration is generally beneficial.

  • Cytotoxic chemotherapy (cisplatin, doxorubicin) and radiotherapy: Caution. Niacinamide is a deliberate radiosensitiser and modulates PARP-dependent repair, so its use during active cancer treatment is a decision for the treating oncology team rather than a self-directed one.

  • Aspirin and non-steroidal anti-inflammatory drugs: Monitor. These slow niacinamide clearance, raising plasma levels at a given dose. No clinical consequence has been documented; the interaction matters only at multi-gram intakes.

  • Other NAD⁺ precursors (nicotinic acid, NR, NMN): Caution, additive. All converge on the same methylation-dependent disposal route, so stacking multiplies methyl-group demand and terminal-metabolite load. Use one precursor, not several.

  • Methyl donors (betaine, choline, methylfolate, methylcobalamin): Additive in the useful direction. Co-administration offsets the betaine depletion and homocysteine rise documented by Sun et al., 2017. Commonly paired with gram-level protocols.

  • Intestinal phosphate binders (sevelamer, lanthanum carbonate): Caution, additive. Niacinamide lowers phosphate by a different mechanism, so combination risks hypophosphataemia (abnormally low blood phosphate) and compounds gastrointestinal intolerance.

  • Alcohol: Monitor. Both load the same hepatic clearance machinery; heavy intake alongside multi-gram niacinamide raises the chance of the transaminase elevations documented in the safety review.

  • Topical retinoids (tretinoin, adapalene) and alpha-hydroxy acids (glycolic acid, lactic acid): Caution. Layering with niacinamide increases stinging and desquamation. Separating application by time of day, or alternating nights, resolves it without dropping either agent.

Populations who should avoid Niacinamide:

  • Established liver disease at Child-Pugh Class B or C, or transaminases above three times the upper limit of normal
  • Advanced kidney disease with eGFR below 30 mL/min/1.73 m² outside a phosphate-management protocol supervised by a nephrologist
  • Active peptic ulcer disease or inflammatory bowel disease in flare, at doses above 500 mg daily
  • Pregnancy and lactation at doses above the recommended dietary allowance of 14–18 mg niacin equivalents daily
  • Active cancer treatment involving radiotherapy or PARP-directed agents, unless directed by the treating oncologist

Risk Mitigation Strategies

  • Cap the daily dose at 1 g: 500 mg twice daily is the dose at which chemoprevention was demonstrated without excess digestive adverse events, avoiding the gastrointestinal and hepatic risks that scale above 1.5 g.

  • Split doses and take with food: Two or three divided doses with meals blunt the peak gut concentration that drives nausea and diarrhoea, the single most common reason people stop.

  • Co-supplement methyl donors: 500–1,000 mg trimethylglycine (betaine) daily, or an equivalent choline source, offsets the betaine depletion and homocysteine elevation documented after nicotinamide dosing.

  • Check liver enzymes at baseline, 3 months, then annually: Catches the reversible transaminase elevation described in the safety review while it is still asymptomatic, and before dose escalation compounds it.

  • Track homocysteine at baseline and 3 months: Directly measures whether methyl-group demand is outrunning supply, which is the mechanism behind the depletion risk rather than a proxy for it.

  • Use one NAD⁺ precursor only: Stacking niacinamide with nicotinic acid, NR or NMN multiplies terminal-metabolite production, the exposure implicated in the cardiovascular signal, without evidence of additive benefit.

  • Patch-test topical products and separate from acids: Applying 5% niacinamide to a small area for three nights, and not layering it with low-pH acids in the same session, prevents the stinging and desquamation that cause abandonment.

  • Escalate slowly toward multi-gram protocols: Increasing by 500 mg every one to two weeks toward 1.5–3 g identifies the individual gastrointestinal ceiling before it produces an abrupt stop.

Therapeutic Protocol

  • Standard chemoprevention dose: 500 mg twice daily, indefinitely. This is the regimen validated in ONTRAC and reproduced in the veterans cohort, popularised by Damian and Halliday’s dermatology group at the University of Sydney.

  • Competing high-dose neuroprotection approach: 1.5–3 g daily in divided doses, as used in the Melbourne and Columbia glaucoma trials. Presented as an alternative rather than a default, since the validated visual endpoint has not moved.

  • Competing topical-only approach: 4–5% niacinamide applied twice daily, with no oral component. Favoured in cosmetic dermatology where the target is skin appearance or acne rather than cancer incidence.

  • Time of day: No circadian advantage has been demonstrated. Doses are anchored to meals to limit nausea, which in practice means morning and evening with food.

  • Half-life and dose splitting: Plasma half-life of a few hours makes single daily dosing unsuitable above 500 mg. Blood NAD⁺ itself plateaus only after about two weeks of daily dosing (Berven et al., 2026).

  • Genetic considerations: Reduced-function MTHFR or COMT variants raise the methyl cost of clearance, favouring the 1 g ceiling plus a methyl donor rather than multi-gram escalation.

  • Sex-based considerations: Fixed milligram dosing gives women higher exposure per kilogram. No efficacy difference is documented, but the chemoprevention evidence base is overwhelmingly male.

  • Age-based considerations: Adults over 70 gain the most from chemoprevention because of accumulated sun damage, while reduced renal clearance argues against exceeding 1 g daily in that group.

  • Baseline biomarkers driving dose: Low serum niacinamide, elevated phosphate in advanced kidney disease, and a first keratinocyte carcinoma are the three baseline states linked to a measurable response.

  • Pre-existing conditions driving dose: Pharmacological immunosuppression predicts no chemoprevention benefit; liver or advanced kidney disease caps the dose; prediabetes argues for glucose monitoring at multi-gram intakes.

Discontinuation & Cycling

  • Lifelong for chemoprevention: ONTRAC found no residual benefit in the six months after stopping, so protection tracks current use rather than cumulative exposure. Stopping returns risk to baseline.

  • No withdrawal syndrome: Niacinamide produces no dependence or rebound. Doses at or below 3 g daily have been stopped abruptly in every major trial without adverse consequence.

  • No taper required: Because there is no withdrawal effect, tapering serves no pharmacological purpose. It is reasonable only when stepping down from multi-gram doses to confirm which symptoms were drug-related.

  • Cycling not established: No trial has tested intermittent dosing, and the loss of benefit after stopping argues against it for chemoprevention. Some practitioners cycle multi-gram protocols to limit methyl-group demand.

  • Topical discontinuation: Barrier and pigment effects reverse over roughly the same 8–12 weeks they took to appear, since the mechanism depends on continuing synthesis rather than a lasting structural change.

Sourcing and Quality

  • Choose the right molecule: Labels reading “niacin”, “no-flush niacin” or “inositol hexanicotinate” are not niacinamide. Only “niacinamide” or “nicotinamide” delivers the compound studied here, and only nicotinic acid has lipid effects.

  • Insist on third-party testing: ConsumerLab’s testing found 19% of selected B vitamin products contained far more or far less of at least one B vitamin than claimed, making independent verification the main quality lever.

  • Look for USP or NSF certification: These marks, from the United States Pharmacopeia and NSF International, verify identity, potency and contaminant limits. For a single-ingredient, cheap vitamin, certification costs little and removes the dominant failure mode of mislabelled content.

  • Prefer single-ingredient capsules over B-complexes: Reaching 1 g of niacinamide through a complex delivers large, unintended doses of every other B vitamin, including nicotinic acid, biotin and pyridoxine.

  • Reputable brands and compounders: Thorne, Pure Encapsulations, NOW Foods, Douglas Laboratories and Life Extension all supply single-ingredient niacinamide; compounding pharmacies can supply the 500 mg dermatology dose where retail sizes do not match.

  • Topical formulation matters: Effective trials used 4–5% niacinamide at near-neutral pH. Lower concentrations are common in cosmetics, and acidic formulations can convert niacinamide to flushing-capable nicotinic acid.

Practical Considerations

  • Time to effect: Actinic keratoses fell measurably by three months in ONTRAC and skin cancer counts by twelve. Topical appearance changes need 8–12 weeks; blood NAD⁺ plateaus at about two weeks.

  • Pitfall — confusing the two forms: Buying nicotinic acid expecting a flush-free experience, or buying niacinamide expecting cholesterol change, are the two most common errors. The forms are not interchangeable.

  • Pitfall — stacking precursors: Combining niacinamide with NR or NMN adds cost and methyl-group demand without evidence of additive benefit, since all three converge on the same salvage pathway and disposal route.

  • Pitfall — treating it as a one-off course: Benefit tracks current use. Stopping after twelve months, as trial participants did, returns skin cancer rates to the untreated level within six months.

  • Regulatory status: In the United States niacinamide is a dietary supplement and a permitted cosmetic ingredient, not an approved drug for any indication discussed here. Chemoprevention use is therefore entirely off-label.

  • Cost and payer incentives: At USD 5–15 monthly it is far cheaper than the excisions it may displace, and an economic evaluation found it cost-saving. Insurers favour it; no manufacturer profits enough to fund confirmatory trials, leaving this literature dependent on public funders.

Interaction with Foundational Habits

  • Sleep: No direct interaction is demonstrated. The indirect link is that the NAMPT enzyme feeding NAD⁺ oscillates on a circadian schedule, so the pathway is clock-linked, but no controlled trial has measured sleep quality, latency or architecture on niacinamide. Evening dosing is chosen for meal timing, not for sleep.

  • Nutrition: Direct and two-way. Dietary tryptophan and fortified grains already supply niacin equivalents, reducing headroom, while niacinamide clearance depletes betaine and choline. Practical response: include beetroot, spinach, eggs and liver, or supplement trimethylglycine, and take doses with food to blunt nausea.

  • Exercise: Potentiating in the same direction. Training upregulates intracellular NAMPT expression in humans (Sun et al., 2023), the enzyme that converts niacinamide into the NAD⁺ pool, so exercise plausibly increases what a given dose yields. No blunting of hypertrophy or endurance adaptation has been reported, and no timing requirement around workouts exists.

  • Stress management: Indirect only. Niacinamide supports mitochondrial energy production, which stress depletes, but no controlled human study has measured cortisol, heart rate variability or perceived stress on niacinamide. Practically, it neither substitutes for nor interferes with stress-reduction practices.

Monitoring Protocol & Defining Success

Before starting gram-level niacinamide, establish a baseline covering the three organ systems where documented effects sit: liver, kidney and the methylation pathway. That means a liver panel with alanine and aspartate aminotransferase, creatinine with estimated glomerular filtration rate, fasting glucose with glycated haemoglobin, plasma homocysteine, and — for anyone using it for skin cancer prevention — a dated dermatological lesion count, which is the only endpoint that defines success for that indication. Serum phosphate belongs in the baseline only for people with advanced kidney disease.

Ongoing monitoring follows a simple cadence: repeat liver enzymes and homocysteine at 3 months, then annually if stable; repeat kidney function and glucose markers annually; and schedule dermatological review every 6 months, since new lesion counts, not laboratory values, determine whether the intervention is working.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–26 U/L (men), 8–22 U/L (women) Earliest signal of the reversible hepatic effect at gram doses ALT is alanine aminotransferase, a liver enzyme. Conventional labs flag only above 40–55 U/L; the functional ceiling is far lower. Fasting preferred
AST 10–26 U/L Confirms an ALT rise is hepatic rather than muscular AST is aspartate aminotransferase. Conventional labs flag only above 40 U/L. Pair with creatine kinase if recent intense exercise; AST rises with muscle damage too
Homocysteine Below 8 µmol/L Directly tracks whether methyl-group demand is outrunning supply Conventional cutoff is 15 µmol/L, far above the functional target. Fasting sample; process promptly or the value drifts upward
Fasting glucose 75–86 mg/dL Detects the inconsistent insulin-resistance signal at multi-gram doses 12-hour fast. Conventional reference range runs to 99 mg/dL, well above the functional ceiling. Best paired with fasting insulin to calculate insulin resistance rather than read glucose alone
HbA1c 4.8–5.3% Confirms whether a single glucose reading reflects a sustained shift HbA1c is glycated haemoglobin, a 3-month average of blood sugar. Conventional labs flag only at 5.7% and above. No fasting needed. Falsely low with shortened red cell lifespan
eGFR Above 90 mL/min/1.73 m² Governs clearance of niacinamide and both terminal metabolites eGFR is estimated glomerular filtration rate. Conventional labs flag only below 60 mL/min/1.73 m². Creatinine-based values overestimate in high-muscle-mass individuals; cystatin C is the better paired test
Serum phosphate 2.5–4.0 mg/dL Relevant only in advanced kidney disease, where niacinamide lowers it Conventional upper limit is 4.5 mg/dL. Rises through the day; draw fasting in the morning. Combining with a phosphate binder risks over-suppression
Fasting insulin 2–5 µIU/mL Detects the insulin-resistance signal before fasting glucose moves Conventional reference range extends to about 25 µIU/mL, five times the functional ceiling. Must be drawn in the same fasting sample as glucose so the two can be combined into an insulin-resistance index rather than read separately
Dermatological lesion count No established target — track change from the individual’s own baseline count of keratinocyte carcinomas and actinic keratoses The only endpoint that defines success for chemoprevention Requires a dated full-skin examination by a dermatologist, not self-assessment. Photographic mapping improves comparability between visits

Qualitative markers worth tracking alongside the laboratory values:

  • Gastrointestinal comfort — nausea, bloating or loose stools within an hour of dosing are the earliest sign the dose exceeds individual tolerance
  • Skin barrier feel — reduced tightness, flaking and reactivity after 8–12 weeks of topical use
  • Visible skin appearance — blotchiness, sallowness and pigment spots, best judged from standardised monthly photographs rather than memory
  • Energy through the afternoon, as an informal proxy for mitochondrial substrate availability, acknowledging it is highly susceptible to expectation
  • Absence of new acne lesions across a full menstrual or seasonal cycle, which is the shortest interval that averages out normal fluctuation

Emerging Research

  • NAMinG phase III glaucoma trial: NCT05405868 randomises 496 people with open-angle glaucoma to niacinamide or placebo, with visual field mean deviation at 27 months as the primary endpoint — the validated endpoint the phase II trials failed to move.

  • Glaucoma Nicotinamide Trial: NCT05275738 enrols 660 participants at Umeå University with visual field progression as the primary outcome, making it the largest niacinamide eye trial and a direct test of whether electrical improvements translate into preserved sight.

  • Singapore glaucoma supplementation trial: NCT06731582 is a phase 3 study of 520 participants using mean deviation as its primary measure, adding an East Asian population to a literature drawn from Australia, Korea and the United States.

  • Transplant chemoprevention pivotal trial: NCT05955924 enrols 396 solid organ transplant recipients, powered on time to first keratinocyte carcinoma. It directly retests the population where ONTRANS stopped early for poor recruitment and found nothing.

  • Ileocolonic-release niacinamide in ulcerative colitis: NCT06488625 is a phase 2/3 trial in 459 patients testing a formulation designed to deliver niacinamide to the colon, opening an indication unrelated to skin or eye and dependent on local rather than systemic exposure.

  • Evidence that could weaken the case — terminal metabolites: Ferrell et al., 2024 tied 2PY and 4PY to cardiovascular events across three cohorts. Whether long-term gram-level niacinamide raises these metabolites enough to matter is the open question this line of work poses.

  • Evidence that could weaken the case — negative endpoint trials: Grill et al., 2025 found 3 g daily for 48 weeks did not alter Alzheimer’s biomarkers, and Tosti et al., 2023 found no pooled skin cancer reduction, tempering extrapolation beyond sun-damaged skin.

  • Health-economic and pharmacokinetic groundwork: Perez et al., 2026 found chemoprevention cost-saving, and Berven et al., 2026 showed blood NAD⁺ needs two to four weeks of dosing to plateau — a dosing-duration constraint most earlier trials did not account for.

Conclusion

Niacinamide is the flush-free form of vitamin B3 and the cheapest way to feed the body’s supply of the helper molecule that drives cellular energy and repair of damaged genetic material. Its strongest human evidence is narrow and skin-centred: creams containing it improve the look of sun-aged and blemish-prone skin, and gram-level capsules lower the number of new common skin cancers in people who have already had several. That last finding is unsettled — one large trial and one pooled analysis found a clear reduction, while a trial in transplant recipients and a second pooled analysis found none, and the benefit looks largest when treatment starts soon after a first skin cancer. Outside the skin, results thin out. Well-run trials aimed at delaying type 1 diabetes and at slowing early Alzheimer’s disease found nothing, and eye trials so far show changes in electrical recordings of the retina without matching gains in sight.

Harm at ordinary supplement amounts is minimal. At gram-level intakes, stomach upset is common enough to stop people taking it, liver enzymes occasionally rise, and clearing the vitamin consumes a chemical tag that many other reactions need. Separately, observational work links the breakdown products of excess vitamin B3 to heart risk, while the trials themselves recorded no excess heart events.

Most free consumer material on this vitamin comes from companies that sell it. The trials carrying the evidence were paid for by public funders, because nobody can patent a vitamin.

Top - Benefits - Risks - Protocol